Table 1 Baseline characteristics of all 94 patients
Total (n = 94) | |
|---|---|
Demographic data | |
Age (years) | 45.8 ± 19.6 |
Female (%) | 62.8 |
BMI (kg/m2) | 27.4 ± 6.7 |
Surgical Approach (%) | |
MIC | 77.7 |
Sternotomy | 22.3 |
Preoperative medication (%) | |
Pyridostigmin | 83.9 |
Cortisone | 72.2 |
Other Immunosuppressants | 28.7 |
Myocphenolatmophetil | 3.8 |
Azathioprin | 27.5 |
Rituximab | 2.2 |
Preoperative IVIg-therapy (%) | 6.1 |
Clinical classification (%) | |
TAMG | 22.3 |
EOMG | 47.9 |
LOMG | 29.8 |
Preoperative MGFA-Stage (%) | |
I | 16 |
IIA | 36.2 |
IIB | 21.1 |
IIIA | 7.4 |
IIIB | 5.3 |
IVA | 5.3 |
IVB | 3.2 |
V | 1.1 |
Perioperative antibody positive (%) | |
Acetylcholine | 78.7 |
MuSK | 3.8 |
Titin | 19.8 |
ICU-stay (days) | 1 [0;16] |
Hospital stay (days) | 8.5 ± 8.4 |
Thymoma | |
Masaoka-Koga Stage (%) | |
I | 18.0 |
IIA | 2.0 |
III | 1.0 |
WHO Stage (%) | |
Type A | 4.8 |
Type AB | 28.6 |
Type B1 | 38.1 |
Type B2 | 19.0 |
Type B3 | 9.5 |
Follow up in months (WHO-Stage) | months |
Type A | 7.8 ± 0.0 |
Type AB | 45.2 ± 44.2 |
Type B1 | 24.9 ± 20.3 |
Type B2 | 23.4 ± 19.4 |
Type B3 | 46.4 ± 21.9 |